Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

"Safety is primary focus for all our vaccines": Covaxin-developer Bharat Biotech amid reports on AstraZeneca vaccine

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." Read further on Dynamite News:

Dynamite News

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’

Controversy over Covishield safety reaches Supreme Court, petition seeks expert panel to study risk factors and vaccine consequences.

The Hindu

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca's £18.7m boss Soriot bounces back as pharma giant reveals 18% sales growth

Soriot came under fire this month for his £18.7 million pay packet

Evening Standard

There's still plenty of shares to like on the poor old FTSE 100

City Voices: Taken together, London’s top flight mightn’t look so appealing. But that doesn’t mean that all UK stocks should be written off.

Evening Standard

3 Biotech Stocks with Potential Gains - Watch or Buy?

The biotech industry’s growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more.

StockNews.com

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Astrazeneca Shareholders Approve CEO Pay Policy For 2024

AstraZeneca shareholders approve 2024 pay policy, showing confidence in CEO Soriot's leadership and company's future growth.

Top News

AstraZeneca CEO’s £18.7m pay approved despite shareholder rebellion

Third of voters reject Pascal Soriot’s deal but some say it is deserved as he had been ‘massively underpaid’

The Guardian - UK

FTSE 100 Live 11 April: Shares edge lower before ECB rates ca, Lok'nStore bought out by Shurgard for £378m

A new pay deal for AstraZeneca boss Pascal Soriot and the fallout from yesterday’s US inflation shock are among areas of focus for London traders.

Evening Standard

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

Barchart

Experts say Medicaid rebate change is behind inhaler price cuts - Roll Call

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

Roll Call

Fusion Rockets 99%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover

AstraZeneca said Tuesday is would acquire Fusion Pharmaceuticals for $2 billion upfront. The biotech stock nearly doubled.

Investors Business Daily

AstraZeneca to buy Canadian cancer specialist Fusion for $2.4bn

Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

When £17m isn’t enough: FTSE firms plead to pay bosses millions more

Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier

The Guardian - UK

‘A cut-and-paste budget’: UK businesses attack lack of help from chancellor

Hospitality trade says chancellor failed to help save sector with VAT cut, while travel industry laments air duty rise

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

The Guardian - UK

A quiet conspiracy is afoot to give FTSE 100 executives a pay rise

As the London market’s woes are blamed on remuneration, a new US benchmark is emerging

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Large COVID-19 vaccine study finds risks

Any pharmaceutical has risk of side effects, but a COVID infection is far more dangerous than the vaccines

The Guardian - AU

Two very rare Covid vaccine side-effects detected in global study of 99 million

Results confirm how uncommon known complications are as researchers confirm benefits from vaccines still ‘vastly outweigh the risks’

The Guardian - AU

Afternoon Update: Woolworths shares plunge; NZ MP dies after charity run; and AstraZeneca boss’s $33m paycheque

Supermarket giant’s CEO resigns unexpectedly amid increasing political pressure over record profits during cost-of-living crisis

The Guardian - UK

AstraZeneca boss’s £17m pay package under fire

Corporate governance thinktank questions whether Pascal Soriot’s remuneration – 1,000 times the minimum wage – is justifiable

Medical Daily

COVID Vaccines Linked To Slight Increase In Heart And Brain Issues: Large-Scale Study

The researchers cautioned that the study found only associations with adverse health effects and it does not prove that these issues are caused by the vaccines.

The Guardian - UK

Weight-loss drugs need to become cheaper, says AstraZeneca boss

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

Investors Business Daily

AstraZeneca Nose Dives On 'Thoroughly Underwhelming' Fourth-Quarter Results

AstraZeneca's quarterly results were "thoroughly underwhelming," an analyst said Thursday as he downgraded AZN stock to a sell rating.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.